Special Issue

Colorectal Liver Metastasis (Volume II)

Message from the Guest Editors

Colorectal cancer is one of the leading causes of cancer-related deaths, presenting an advanced stage at diagnosis in more than 20% of patients, with the liver being the most common metastatic site. Surgery is considered the only curative treatment but cannot be carried out in up to 80% of cases. For patients with unresectable liver metastases, image-guided thermal ablations and radiation therapy have been proposed as effective and safe therapeutic options with curative intent. Several improvements have also been achieved in the systemic therapy for patients with unresectable disease, aimed at disease control and survival improvement. Other treatment strategies, such as transarterial chemoembolization or radioembolization. have been applied and represent promising treatment options for patients. In this Special Issue, the state of the art and most recent innovations in the treatment of colorectal liver metastases will be presented and discussed.

Guest Editors

Prof. Dr. Guido Torzilli

Director of Department of Surgery, Division of Hepatobiliary Surgery & General Surgery, Humanitas Research Hospital, 20089 Rozzano, Italy

Dr. Guido Costa

- 1. Department of Biomedical Science, Humanitas University, Via Rita Levi Montalcini 4, 20072 Pieve Emanuele, Milan, Italy
- 2. Department of Hepatobiliary and General Surgery, IRCCS Humanitas Research Hospital, Via Alessandro Manzoni 56, 20089 Rozzano, Italy

Deadline for manuscript submissions

closed (20 October 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



mdpi.com/si/134364

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/ cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.5 CiteScore 8.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, LISA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

